Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 65(22): 15066-15084, 2022 11 24.
Article in English | MEDLINE | ID: mdl-36346645

ABSTRACT

Ca2+/calmodulin-dependent protein kinase II alpha (CaMKIIα) is a brain-relevant kinase and an emerging drug target for ischemic stroke and neurodegenerative disorders. Despite reported CaMKIIα inhibitors, their usefulness is limited by low subtype selectivity and brain permeability. (E)-2-(5-Hydroxy-5,7,8,9-tetrahydro-6H-benzo[7]annulen-6-ylidene)acetic acid (NCS-382) is structurally related to the proposed neuromodulator, γ-hydroxybutyric acid, and is a brain-penetrating high nanomolar-affinity ligand selective for the CaMKIIα hub domain. Herein, we report the first series of NCS-382 analogs displaying improved affinity and preserved brain permeability. Specifically, we present Ph-HTBA (1i) with enhanced mid-nanomolar affinity for the CaMKIIα binding site and a marked hub thermal stabilization effect along with a distinct CaMKIIα Trp403 flip upon binding. Moreover, Ph-HTBA has good cellular permeability and low microsomal clearance and shows brain permeability after systemic administration to mice, signified by a high Kp, uu value (0.85). Altogether, our study highlights Ph-HTBA as a promising candidate for CaMKIIα-associated pharmacological interventions and future clinical development.


Subject(s)
Benzocycloheptenes , Brain , Calcium-Calmodulin-Dependent Protein Kinase Type 2 , Animals , Mice , Benzocycloheptenes/pharmacology , Binding Sites , Brain/metabolism , Protein Binding , Calcium-Calmodulin-Dependent Protein Kinase Type 2/antagonists & inhibitors
2.
J Med Chem ; 65(9): 6656-6676, 2022 05 12.
Article in English | MEDLINE | ID: mdl-35500061

ABSTRACT

The Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα) is a brain-relevant kinase involved in long-term potentiation and synaptic plasticity. We have recently pinpointed the CaMKIIα hub domain as the long-sought-after high-affinity target of γ-hydroxybutyrate ligands substantiated with a high-resolution cocrystal of 5-hydroxydiclofenac (3). Herein, we employed in silico approaches to rationalize and guide the synthesis and pharmacological characterization of a new series of analogues circumventing chemical stability problems associated with 3. The oxygen-bridged analogue 4d showed mid-nanomolar affinity and notable ligand-induced stabilization effects toward the CaMKIIα hub oligomer. Importantly, 4d displayed superior chemical and metabolic stability over 3 by showing excellent chemical stability in phosphate-buffered saline and high resistance to form reactive intermediates and subsequent sulfur conjugates. Altogether, our study highlights 4d as a new CaMKIIα hub high-affinity ligand with enhanced pharmacokinetic properties, representing a powerful tool compound for allosteric regulation of kinase activity with subtype specificity.


Subject(s)
Calcium-Calmodulin-Dependent Protein Kinase Type 2 , Diclofenac , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Diclofenac/analogs & derivatives , Ligands , Long-Term Potentiation
3.
J Med Chem ; 62(5): 2798-2813, 2019 03 14.
Article in English | MEDLINE | ID: mdl-30763084

ABSTRACT

Gabazine, a γ-aminobutyric acid type A (GABAA) receptor antagonist, has previously been reported to inhibit the binding of [3H]NCS-382, a representative ligand of the high-affinity binding site for the neuroactive substance γ-hydroxybutyric acid (GHB). We herein report a study on the structural determinants of gabazine for binding to (i) the orthosteric binding site of the GABAA receptor and (ii) the high-affinity GHB binding site. Expanding the structural diversity of available ligands for the high-affinity GHB binding sites, this study identified 2-(imidazo[1,2- b]pyridazin-2-yl)acetic acid as a novel ligand-scaffold leading to analogues with relatively high affinity ( Ki 0.19-2.19 µM) and >50 times selectivity for the [3H]NCS-382 over [3H]muscimol binding sites. These results highlight that gabazine interacts with the high-affinity GHB and orthosteric GABAA receptor binding sites differently and that distinct analogues can be generated to select between them. To facilitate further in vivo studies, a promising prodrug candidate for brain delivery was identified.


Subject(s)
Acetic Acid/chemistry , Drug Discovery , Hydroxybutyrates/metabolism , Imidazoles/chemistry , Pyridazines/pharmacology , Animals , Binding Sites , Ligands , Male , Mice , Mice, Inbred C57BL , Pyridazines/chemistry , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship
4.
J Med Chem ; 60(21): 9022-9039, 2017 11 09.
Article in English | MEDLINE | ID: mdl-29028338

ABSTRACT

γ-Hydroxybutyric acid (GHB) is a neuroactive substance with specific high-affinity binding sites. To facilitate target identification and ligand optimization, we herein report a comprehensive structure-affinity relationship study for novel ligands targeting these binding sites. A molecular hybridization strategy was used based on the conformationally restricted 3-hydroxycyclopent-1-enecarboxylic acid (HOCPCA) and the linear GHB analog trans-4-hydroxycrotonic acid (T-HCA). In general, all structural modifications performed on HOCPCA led to reduced affinity. In contrast, introduction of diaromatic substituents into the 4-position of T-HCA led to high-affinity analogs (medium nanomolar Ki) for the GHB high-affinity binding sites as the most high-affinity analogs reported to date. The SAR data formed the basis for a three-dimensional pharmacophore model for GHB ligands, which identified molecular features important for high-affinity binding, with high predictive validity. These findings will be valuable in the further processes of both target characterization and ligand identification for the high-affinity GHB binding sites.


Subject(s)
Carboxylic Acids/chemistry , Crotonates/chemistry , Cyclopentanes/chemistry , Hydroxybutyrates/chemistry , Models, Molecular , Binding Sites , Carboxylic Acids/chemical synthesis , Carboxylic Acids/metabolism , Crotonates/chemical synthesis , Crotonates/metabolism , Cyclopentanes/chemical synthesis , Cyclopentanes/metabolism , Drug Design , Ligands , Molecular Conformation , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...